(redirected from Symlin)
Also found in: Medical.


An injectable drug that is a synthetic analog of the hormone amylin, used in the form of its acetate salt to treat type 1 and type 2 diabetes.

[pram-, of unknown origin + -lintide, amylin derivative or mimic suffix ((amy)lin + (pep)tide).]


n pramlintida
References in periodicals archive ?
Pramlintide (Symlin; AstraZeneca, Cambridge, United Kingdom), a synthetic amylin analog, lowers the glycated hemoglobin (HbA1c) level in patients with type 1 and 2 diabetes, slows down gastric emptying, reduces appetite, and exerts favorable effects on body weight.
Lexi Pharma team members have collectively filed 15 New Drug Applications and have been involved in the development and launch of successfully marketed products including: Byetta, Bydureon, Camptosar, Dacogen, Ellence, Emcyt, Erbitux, Folotyn, Panretin, Symlin, Sutent, Targretin, Vidaza, Velcade, and Zarnestra.
The medication, pramlintide (Symlin), slows the absorption of food and may cause some weight loss, according to the ADA.
Amitriptyline* Elavil Bupropion * Wellbutrin, Zyban Clomipramine* Anafranil Desipramine* Norpramin Exenatide* Byetta, Bydureon Imipramine* Tofranil Levomilnacipran * Fetzima Liraglutide * Victoza, Saxenda Lorcaserin * Belviq Metformin * Glucophage Methylphenidate * Ritalin, Methylin Mirtazapine* Remeron Naltrexone/bupropion * Contrave Nefazodone * Serzone Nortriptyline* Pamelor Olanzapine* Zyprexa Orlistat* Xenical Paroxetine * Paxil Phentermine/topiramate * Qsymia Pramlintide* Symlin Protriptyline* Vivactil Quetiapine* Seroquel Trazodone * Desyrel, Oleptro Vilazodone* Viibryd Vortioxetine * Trintellix Zonisamide * Zonegran
suspension), Myalept (metreleptin) and Symlin (pramlintide acetate).
"In obese patients with [type 2 diabetes] requiring insulin therapy, we suggest adding at least one of the following: metformin, pramlintide (Symlin), or GLP-1 (glucagonlike peptide-1 receptor) agonists to mitigate associated weight gain due to insulin," they noted.
With the acquisition, AstraZeneca possess the intellectual property and global rights for the development, manufacture, and commercialization of BMS diabetes business, which comprises Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin HCl extended release), Komboglyze (saxagliptin and metformin HCl), dapagliflozin (marketed as Forxiga outside the US and Farxiga in the US), Xigduo (dapagliflozin and metformin HCl), Byetta (exenatide), Bydureon (exenatide extended-release for injectable suspension), metreleptin, and Symlin (pramlintide acetate).
The acquisition offers AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, including Onglyza, Kombiglyze XR, Komboglyze, dapagliflozin, Xigduo, Byetta, Bydureon, metreleptin and Symlin.
* Pramlintide (Symlin) also is an injectable drug for treatment of type 1 and type 2 diabetes.
Other drugs include recently approved Symlin (Pramlintide Acetate), as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy, and Levemir (Insulin Detemir) which is indicated for once or twice daily subcutaneous administration in the treatment of adult patients with Type 1 DM who require basal (long-acting) insulin for the control of hyperglycemia.
Amylin analogues: Pramlintide (Symlin) was developed in New Zealand.
There is no human pregnancy experience with pramlintide (Symlin), a synthetic analogue of human amylin given by subcutaneous injection, but the animal data suggest moderate risk (structural anomalies in rats).